feed,title,long_url,short_url
Benzinga,"Viridian Therapeutics' Lead Product Has An Opportunity To Differentiate, Analyst Sees 85% Upside",https://benzinga.com/analyst-ratings/analyst-color/22/12/30111941/viridian-therapeutics-lead-product-has-an-opportunity-to-differentiate-analyst-sees,https://da.gd/qRHtas
Benzinga,"Some 'Transgenic Animal Platforms Are More Than Equal,' Analyst Initiating Coverage On OmniAb Says",https://benzinga.com/analyst-ratings/analyst-color/22/12/30111844/some-transgenic-animal-platforms-are-more-than-equal-analyst-initiating-coverage-on,https://da.gd/6qxwJ
